Opera Trading Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Opera Trading Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-13,400	Closed	-$1.3M	–	96
2018 Q3	$1.3M	Buy	+13,400	New	+$1.34M	0.25%	64
2016 Q3	–	Sell	-13,200	Closed	-$1.03M	–	114
2016 Q2	$1.03M	Hold	13,200	–	–	0.22%	61
2016 Q1	$1.09M	Buy	+13,200	New	+$1.07M	0.29%	65

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opera Trading Capital's BMRN Position: Q4 2018 in Review

Opera Trading Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2018, closing a stake of 13,400 shares — an estimated $1.3M sold.

Opera Trading Capital first reported a position in BMRN in Q1 2016 and held it in 3 quarters. The position peaked at $1.3M in Q3 2018. 472 funds tracked by Wall St. Rank hold BMRN as of Q4 2018.

Opera Trading Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Opera Trading Capital sold 13,400 BioMarin Pharmaceuticals shares in Q4 2018, an estimated $1.3M.
Opera Trading Capital first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 3 quarters.
Opera Trading Capital's BioMarin Pharmaceuticals position peaked at $1.3M in Q3 2018.
472 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.